
Opinion|Videos|August 30, 2024
Insights on Conjugate Pneumococcal Vaccines
The vaccination experts analyze the impact of currently approved pneumococcal vaccines on otitis media prevention and compare the newer conjugate vaccines (PCV15 and PCV20) to their predecessors in terms of strain coverage and clinical efficacy.
Advertisement
Episodes in this series

- What effect do currently approved pneumococcal vaccines have on preventing otitis media?
- How do the newer conjugate vaccines (PCV15 and PCV20) compare to their predecessors in terms of strain coverage and clinical efficacy?
- What are your considerations for selecting between conjugate vaccines for adult patients who are vaccine-naïve?
- When would you use PCV20 instead of PCV15 and vice versa?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Expands Approval of Sotatercept-csrk for Pulmonary Arterial Hypertension
2
States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments
3
Clinical Data Support Use of Low-Carbon Version of Albuterol Metered Dose Inhaler for Asthma
4
Expert Insights on Key Data from IMS 2025
5














































































































































































































